Insights Newsletter April 2024

Dear Reader :

This month’s newsletter, co-developed by the IPA and Citeline, spotlights shifts in the pharma pecking order in Germany and progress in an open-science oncology drug development partnership effort being shaped by the US FDA.

While Boehringer Ingelheim has emerged as Germany’s biggest company by pharma revenues edging out Bayer, we also tell you where things stand on the FDA-initiated collaborative program to develop anti-cancer therapies for ultra-rare tumour indications.

There’s also an interview with the outgoing IFPMA chief, who shares his views on key topics including the World Health Organization’s proposed pandemic treaty.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA

Perspective From Industry Leaders


Don't Compromise The Pharma Innovation System; Says Outgoing IFPMA Head Thomas Cueni	Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
Thomas Cueni is stepping down after seven years at the helm of the International Federation of...	Boehringer Ingelheim has become Germany’s biggest company in the sector by pharma revenues, overtaking its...

Licensing & Collaboration Agreements


Healios Acquires Bankrupt Athersys, Expands Cell Therapy R&D Programs	Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Regenerative medicine-focused Japanese biotech Healios K.K. has acquired its long-time US collaborator Athersys...	Gilead Sciences, Inc. obtained exclusive rights on 28 March to develop and sell Xilio Therapeutics, Inc.’s Phase I...

Next Gen R&D


AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer	Rare Cancer Development Consortium Moving Toward Target Selection
AstraZeneca may just have found a worthy successor to its blockbuster PARP inhibitor drug Lynparza...	National Cancer Institute officials will select the first targets for the US Food and Drug Administration-initiated...

Clinical Trials


Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy	Amylyx’s Relyvrio Withdrawal May Trigger More Public Pledges Based On Confirmatory Trial Data
Roivant Sciences Ltd. said it is poised to take on AbbVie Inc.’s Humira in non-infectious uveitis, a leading cause...	Some may question whether the US Food and Drug Administration will be less willing to exercise regulatory flexibility...

Citeline Contact Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India Mobile: +91 9945273146 Email: poornachandra.tejasvi@citeline.com Client Services: clientservices@citeline.com	IPA Contact Name: Hari Pranav K Email: haripranav.k@ipa-india.org